Some compounding pharmacies are making slight tweaks to the composition of their GLP-1s to sidestep an FDA ban on copying approved semaglutide and tirzepatide products, suggest the findings of a study published July 17 in JAMA Health Forum. Surging demand…
GLP-1s
Connecticut has paused plans to seek federal approval to partner with a generic drug manufacturer to lower the cost of GLP-1 medications, despite a state law requiring the effort, according to a July 16 report from the CT Mirror. Gov.…
Average total payments for GLP-1 users without diabetes rose sharply between 2017 and 2022, even as patients personally paid less out of pocket, according to a Northwestern University study published July 16 in the Journal of the American Heart Association. …
CVS Health CEO David Joyner is skeptical as to whether the evidence backs GLP-1 investment right now. “Everybody intuitively believes these medications create long-term health benefits, but the evidence hasn’t yet demonstrated that paying today’s prices generates enough downstream savings,”…
Novo Nordisk has agreed to evaluate a GLP-1 implant developed by biopharmaceutical company Vivani Medical. The implant, called NPM-139, delivers semaglutide through a titanium reservoir fitted with a membrane containing microscopic channels designed to release the drug at a steady…
Advertisement
A wave of new research and policy developments is reshaping how health system leaders think about GLP-1 medications — from telehealth prescribing gaps to Medicare’s new coverage bridge. Here are six recent findings: 1. The share of employers covering GLP-1s…
Joe Northup, MD, associate professor of surgery at Vanderbilt University School of Medicine and director of metabolic and bariatric surgery at Vanderbilt University Medical Center in Nashville, Tenn., was elected the 40th president of the American Society for Metabolic and…
The federal government has not broadly promoted Medicare’s recent $50-a-month obesity-drug benefit, so two GLP-1 manufacturers, Eli Lilly and Novo Nordisk, are touting it themselves, according to Cost Curve. The Medicare GLP-1 Bridge, which launched July 1, allows eligible Part…
Peptides have become one of the most closely watched regulatory questions in healthcare this summer, with a federal advisory committee vote set for July 23-24 that could reshape what’s legally available to prescribers, wellness clinics and patients nationwide. What are…
The share of employers covering GLP-1s for both diabetes and weight loss has held steady at 36% year over year, according to a survey from the International Foundation of Employee Benefit Plans. The survey was conducted June 2 to June…